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Abstract: Pathogenic Gram-negative bacteria have developed resistance to antibiotics due to their ability in creating an envelope 
on the outer layer of lipooligosaccharides (LOS). The cationic phosphoethanolamine (PEA) decoration of LOS lipid A is regulated 
by lipid A–PEA transferase (EptA) which may serve as a prominent target for developing new antibiotics. The structural 
characterization of Neisserial EptA has provided a structural basis to its catalytic mechanisms and ligand recognition that are 
crucial for inhibitor development. In this study, a combination of pharmacophore– and ligand-based approach has been employed 
to explore novel potent EptA inhibitors among millions of commercially-available compounds and approved drugs. A total of 8166 
hit molecules obtained from ZincPharmer pharmacophore–based screening and PubMed ligand similarity search were further 
examined through individual two-step semi-flexible docking simulation performed in MOE. Best hits were therefore selected based 
on their docking score and consensus of the two docking validations. Free energy of binding calculation suggests that the best 20 
consensus compounds have a stronger binding affinity than EptA natural substrate PEA. Further interaction analyses of selected 
eight ligands demonstrate that these ligands have overall more effective interactions with catalytically–essential residues and metal 
cofactors of EptA. Selected hits can be further analyzed in vitro and examined through a pre-clinical trial. This study provides an 
insight into drug repurposing which may serve as an initial step to develop novel potent EptA inhibitors to combat the virulence of 
multi-drug resistant Gram-negative bacteria. 
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1. INTRODUCTION 
Infections caused by antimicrobial-resistant (AMR) 
bacteria have become a major global burden in public 
health from the past several decades and are increasing 
at an alarming rate [1,2]. Among seven bacterial species 
that become a global concern as they were substantially 
developed resistance against multiple antibiotics, five of 
them are Gram-negative bacteria including Escherichia 
coli, Klebsiella pneumoniae, Salmonella sp., Shigella 
sp., and Neisseria sp. [1]. These bacteria are well known 
for their involvement in various diseases including 
gastroenteritis, pneumonia, typhoid fever, shigellosis, as 
well as gonorrhoea and meningitis, respectively. In this 
so-called “post-antibiotic era [1],” it is estimated by the 
middle of 21st century, the mortality rate caused by AMR 
Gram-negative bacterial infection alone could possibly 
be increased up to ten million deaths a year [3]. 
For years, colistin, a peptide antibiotic of polymyxin 
class, has become the last-resort drug that has been 
effectively used to treat infections caused by Gram- 
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negative bacteria [4]. Colistin composed of a fatty acid 
side chain and cyclic polypeptides enriched with cationic 
amino group that electrostatically interacts with  
negatively-charged phosphate group of 
lipopolysaccharides (LPS) layer in the bacterial outer 
membrane [5]. The interaction eventually leads to the 
penetration of a lipophilic part of colistin into the outer 
membrane, ultimately forms pores that cause 
membrane ruptures and cell lysis [5]. This strategy has 
been successfully treated infections and sepsis for 
decades until bacteria that are normally susceptible to 
colistin have developed a resistance against polymyxins 
[6]. Colistin resistance has been reported in various 
Gram-negative bacteria [7–10] and has been 
characterized to be developed from various mutations of 
LPS biogenesis and regulation [4,11].  
Gram-negative bacteria deploy various strategies 
for gaining resistance to polymyxin-class antibiotics. 
Bacteria might enclave polymyxins using anionic 
polysaccharide capsule [12,13], modify their LPS by 
adding cationic substances to repel positively-charged 
polymyxins [14–16], overexpress their outer membrane 
protein [17], and even completely lost their LPS [11,18]. 
Among these mechanisms, LPS modification is the most 
commonly found strategy to achieve polymyxin 
resistance [6]. LPS can be biochemically modified by 
attaching positively-charged groups such as 
phosphoethanolamine (PEA) to counteract colistin, 
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which is the key resistance mechanism in gonococcal 
and meningococcal pathogens Neisseria gonorrhoeae 
(Ng) and Neisseria meningitidis (Nm) [5,19–22]. In these 
pathogenic Neisseria, the decoration of lipid A, a lipo-
glycan moiety that is the major constituent of LPS, with 
PEA is solely catalyzed by lipid A–PEA transferase A 
(EptA). EptA (EC 2.7.4.30) belongs to alkaline 
phosphatase superfamily assists [3]. EptA assists in 
transferring PEA from phosphatidylethanolamine (PE) to 
the 1 and 4’ phosphate groups of lipid A [5], changing 
the overall outer negative charges of phosphates to 
positive charges of PEA which repulse the positively-
charged colistin. Not only essential for polymyxin 
resistance, PEA attachment to LPS has also been 
associated with the increased meningococcal cell 
adhesion to human epithelial and endothelial cells [23] 
and protection of gonococcal Ng lines to immunological 
systems in mouse genital tract [24]. EptA homologues 
that also catalyze PEA transfer to lipid A have been 
characterized in other Gram-negative bacteria [25–28], 
demonstrating a high conservation of resistance 
mechanism in this bacterial group. Due to the catalytic 
activity and direct involvement of EptA in the 
pathogenicity of Gram-negative bacteria, this enzyme is 
proposed to be a potential drug target as its inhibition 
could prevent their resistance against polymyxins [3]. 
Structural characterization of EptA soluble 
periplasmic domain and its homologues [5,29,30] 
revealed that the catalytic site contains a zinc ion (Zn2+) 
which is tetrahedrally coordinated to Glu240, Thr280, 
Asp452, and His 453 (residue numbers are according to 
the structure of NmEptA, PDB ID: 4KAV [5]). Thr280, 
which appeared in the phosphorylated form in NmEptA, 
is particularly important in EptA catalytic activity as this 
residue is required for PEA transfer from PE to lipid A 
via an enzyme–PEA intermediate [3]. A T280A 
mutagenesis of Mcr-1, an EptA homologue in E. coli, 
also revealed that this site change increased the 
vulnerability of bacterial cells to colistin [30], which 
supports the importance of Thr280 in EptA activity and 
overall resistance. Therefore, targeting these 
catalytically active residues of soluble domain of EptA, 
which responsible of PEA binding and transfer, could be 
a new way to discover novel antibacterial leads capable 
of inhibiting PEA decoration of lipid A. Ultimately, the 
new leads could be further developed and tested to treat 
infections caused by antimicrobial resistant Neisseria 
and other Gram-negative bacteria.   
Here, I report an early investigation of discovering novel 
antibacterial leads from databases containing more than 
a hundred million compounds that target the Gram-
negative bacteria resistance factor EptA. This study 
used a pharmacophore approach which uses structural 
arrangement and interactions between the target protein 
and bound molecules or ligands. This approach resulted 
in more effective inhibitors and stronger predicted 
interactions with target active site than PEA and some 
commercially-available antibiotics. The interaction 
between ligands with the enzyme as well as their binding 
capacity was further assessed and validated through 
molecular docking and dynamics studies. As a result, 20 
potential leads with a better binding capacity than PEA 
were obtained from this study. These leads, which are 
commercially available, may further be tested in vitro 
and in vivo to develop novel antimicrobial drugs that may 
treat Gram-negative bacterial–related diseases. The 
Introduction section should include the background and 
aims of the research in a comprehensive manner, for the 
researchers. 
 
 
2. MATERIALS AND METHODS 
 
2.1. Protein sequence and structural alignment 
 Crystal structure of cytoplasmic soluble Neisseria 
meningitidis lipid A–PEA transferase (NmEptA) was 
selected as a target for this study and obtained from 
Protein Data Bank (PDB) (http://www.rcsb.org/pdb/), 
PDB ID: 4KAY [5]. Sequences of Gram-negative 
bacterial EptA and homologues were obtained from 
UniProt database (http://www.uniprot.org/) for sequence 
analysis. Multiple sequence alignment of these protein 
sequences was done to analyze the conservation of 
catalytically active residues and was performed in 
Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) [31] using 
its default parameters. The alignment result was then 
further analyzed in Geneious software [32] to examine 
residue consensus and degree of conservation. 
Structural alignment of three-dimensional Gram-
negative bacterial EptA structures was performed to 
compare structural features of the protein among 
evolutionarily related bacteria. Structures of EptA 
periplasmic domain and its homologues were obtained 
from PDB, namely 4KAY (Neisseria meningitidis), 4TN0 
(Campylobacter jejuni), and 5K4P (Escherichia coli). 
The structures were superimposed and visualized in 
Maestro [33].  
 
 
2.2. Pharmacophore-based virtual screening and 
compound library preparation 
Potential ligands for were searched based on the 
EptA structure and pharmacophore approach using 
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ZincPharmer (http://zincpharmer.csb.pitt.edu/) that 
utilizes Pharmer algorithm to search potential hits from 
ZINC database [34]. As the structure of EptA bound with 
PEA as the substrate is not available, this complex was 
prepared by re-docking the PEA to EptA active site using 
Molecular Operating Environment (MOE) [35], which 
was then uploaded to the server. The compounds used 
for this virtual screening were deposited in the ZINC 
database (http://zinc.docking.org/), that contains over 
100 million unique purchasable compounds [36]. In total, 
this screening generated 4865 unique compounds 
selected from purchasable compounds, natural 
products, and drugs database of ZINC for further 
validation. Compound library was also prepared by the 
ligand-based approach. Using PubChem 
(https://pubchem.ncbi.nlm.nih.gov/) [37], compounds 
with structural similarity to PEA were screened and 
resulted in 407 compounds with at least 80% similarity. 
In addition, 2000 antibacterials and 894 antibiotics were 
also included in the library. 
All ligands obtained from ZincPharmer and 
PubChem were downloaded in sdf file format. They were 
therefore combined into a single database using MOE, 
generating one MOE database (mdb) file containing a 
total of 8166 ligands. As the structures of these 
compounds were still mostly two-dimensional, therefore 
in a high-energy state, they should be minimized into a 
lower state of energy. This was performed in MOE using 
the protocol as described earlier [38]. First, the ligands 
were protonated to add missing hydrogen in the 
structure using default wash command. After washing, 
the partial charges were corrected and the structures 
were minimized with a 0.05 Å root mean square (RMS) 
gradient using Merck Molecular Force Field 94 
(MMFF94) [39,40]. The library was then ready for 
docking refinement. 
 
2.3. Molecular docking validation and refinement 
To start molecular docking protocol, the crystal 
structure of EptA (PDB ID: 4KAY) was first imported into 
the MOE system. All water and non-protein molecules, 
except zinc ion in the catalytic cavity, were removed as 
the structure underwent energy minimization. The 
protein structure was minimized using AMBER force 
field as it was parameterized for macromolecules such 
as proteins and nucleic acids [41,42]. Missing 
hydrogens in the structure were initially added using 
protonate 3D default command and its partial charges 
were also fixed with AMBER. Then, the structure was 
minimized with an RMS gradient of no more than 0.1 Å. 
For all docking simulations, the catalytic cavity of 
EptA comprises of tetrad Glu240, Thr280, Asp452, and 
His 453, as well as the Zn2+ (ZN602) cofactor, were 
designated as docking targets. There are two-step 
docking protocols that were performed in this study. 
First, the library of initial 8166 ligands was screened to 
obtain top 1000 ligands that have the best score. 
Second, the top 1000 ligands were further refined using 
duplicate docking with two rescoring steps. The initial 
docking validation was performed in MOE using Born 
[43,44] as the solvation method. The placement and 
refinement methods used in this stage were Triangle 
Matcher and Forcefield, respectively. This validation 
retained 30 best ligand positions and removed all 
duplicates. Top 1000 compounds with the best affinity 
and binding score, represented by the free energy (ΔG) 
of binding, were chosen to build a new compound library 
for further refinement. The refinement was done in 
duplicates with additional rescoring parameters, namely 
London dG and Affinity dG, as the first and second 
rescoring respectively. All refinements retained 100 
ligand positions with the highest score and removed any 
possible duplicates. A total of 20 ligands that appeared 
in the top 100 of both refinements were then obtained 
for further interaction analysis. 
 
2.4. Interaction analysis and visualization 
After molecular docking produced ligand poses with 
the highest score, the ligand coordinates were saved 
individually as a MOL file. The ligand coordinate files 
were then re-opened in MOE and placed in the 
previously minimized protein coordinate used in the 
molecular docking protocols. The coordinates of the 
protein-ligand complex were then saved as a PDB file 
for interaction analysis and visualization in Maestro. 
Interaction analyses were done using the Ligand 
Interaction Diagram function in the Maestro. This tool 
allows us to observe non-covalent bonds such as 
hydrogen bond, salt bridge, halogen bond, and aromatic 
H-bond, pi interactions like pi-cation and pi-pi stacking, 
as well as to determine the good, bad, and ugly contacts. 
The ligands were visualized as balls and sticks with 
carbons in green color, whilst the protein residues 
represented as thick tube and grey carbons. 
 
 
3. RESULTS AND DISCUSSIONS 
3.1. Alignment suggests high conservation degree 
of polymyxin resistance mechanism 
Multiple sequence alignment (MSA) of Gram-
negative bacterial lipid A–PEA transferase (EptA) 
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homologues demonstrates a high degree of 
conservation for the catalytically active tetrad comprises 
of Glu240, Thr280, Asp452, and His 453. These 
residues reach a 100% conservation for all 13 assessed 
EptA homologues (Figure 1a).  
 
 
 
Fig. (1). Multiple sequences and structural alignment of EptA 
homologues in Gram-negative bacteria. a) Sequence 
alignment of EptA homologues shows high conservation of 
catalytically active residues (indicated by red arrow) that 
mediated binding with Zn2+ ion and substrate PEA comprise of 
E240, T280, D452, and H453 (annotation based on Neisseria 
meningitidis EptA [5]). Structural superimposition of EptA 
homologues available in PDB: Neisseria meningitidis EptA 
(4KAY; red) [5], Campylobacter jejuni EptC (4TN0; blue) [29], 
and Escherichia coli EptA/Mcr-1 (5K4P; yellow) [30] 
demonstrates that: b) protein folds are conserved and c) 
catalytic tetrads are in the similar position where their side 
chains face the same direction required for correct binding with 
PEA. 
 
The catalytic tetrad observed in NmEptA was 
coordinately-linked with a zinc(II) ion. Although there is 
no direct evidence that these residues actively bind PEA 
and promote PEA transfer, a superposition of NmEptA 
and an alkaline phosphatase, an enzyme that has 
similar activity to EptA, suggests that the tetrad and the 
metal ion are needed for substrate binding [5]. This zinc-
coordinated tetrad, together with other residues in the 
catalytic region such as Glu114, His383, and His465, 
were suggested to assist the binding and transfer of PEA 
from PE to lipid A [3]. A high conservation of catalytic 
tetrad in other EptA homologues suggests that these 
residues are essential for enzymatic activity and the 
catalytic mechanism is likely to be similarly governed in 
all Gram-negative EptA analogues. 
In addition, structural alignment of three periplasmic 
EptA homologues available in PDB shows a highly 
similar architectural arrangement of secondary structure 
(Figure 1b). The superimposition reveals that all three 
EptA structures maintain seven-stranded β-pleated 
sheet that is sandwiched by five α-helices. Further 
observation on the catalytic tetrad also reveals a similar 
conservation. The catalytically important Thr280 
appeared as a phosphorylated form (abbreviated as 
TPO) in all structure (Figure 1c), where the phosphate 
group facing the internal part of the catalytic cavity. 
Similarly, other three residues Glu240, Asp452, and 
His453 are also positioned in similar coordinates whilst 
their side chains also facing the same direction into the 
inner cavity, which appears to be the substrate binding 
pocket. 
Altogether, these alignments show a significant 
degree of conservation in sequence and structural 
aspects and suggest a similar mechanism of substrate 
binding and catalytic activity of EptA analogues in 
bacterial resistance to polymyxin antibiotics. Therefore, 
hit compounds developed from pharmacophore 
screening and docking that target these residues in this 
study may be used to treat not only meningococcal 
diseases but also other Gram-negative bacterial 
infections. 
 
3.2. Ligand library building 
Pharmacophore search is a drug discovery 
approach that employs a spatial arrangement of 
chemical groups of a ligand within the receptor, usually 
the target protein. This method allows researchers in 
exploring structure-activity relationship (SAR) to identify 
chemical compounds with desired activity [45], such as 
a strong interaction and inhibitory activity against a 
protein. Nowadays, this approach is commonly 
performed computationally and arguably one of the most 
established and effective methods of virtual screening 
for rational drug design and discovery [46]. In this study, 
pharmacophore search was performed in ZincPharmer 
(http://zincpharmer.csb.pitt.edu/) [34] which 
accompanies Pharmer pharmacophore search [46] to 
obtained desired compounds from the largest 
compound database, ZINC. In contrast to other 
schemes, Pharmer uses neither fingerprint–based nor 
alignment-based approaches but rather a completely 
new indexing approach [46]. Both fingerprint and 
alignment-based techniques usually assess every 
structural conformer in a library, therefore require more 
times as the size of the library increased. On the 
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contrary, the indexing approach used in Pharmer 
queries conformers based on their geometric 
complexity, therefore it is independent to the size of the 
database which significantly reduces the screening time 
and computational costs [34,46]. Nevertheless, 
pharmacophore search results need to be further 
validated in a more accurate technique, i.e. molecular 
docking to confirm the binding and interaction between 
ligands and the protein. Therefore, a compound library 
from virtual pharmacophore screening needs to be 
established for docking validation.  
In this study, the screening of re-docked EptA bound 
with PEA has provided 4865 screened hits for the 
compound library. The compounds were obtained from 
ZINC database [36] and composed of 2000 purchasable 
compounds, 2000 natural products, and 865 ligands 
from drug database. In addition to the pharmacophore-
searched ligands, the library also included 407 ligand-
based compounds that have at least 80% structural 
similarity to the PEA as well as 2000 antibacterials and 
894 antibiotics which were obtained from PubChem [37]. 
This library then subjected to ligand preparation for 
docking validation. 
As the downloaded structures do not contain 
hydrogens and are two-dimensional, the compound 
structure in the library needs to be corrected and 
energetically minimized. First, the library was protonated 
to add missing hydrogen atoms in the structure using 
Protonate 3D command in MOE. Then, the partial 
charge was corrected and the conformation was energy-
minimized, both using the MMFF94 force field [39,40]. 
MMFF94 is derived from the ab initio computational 
calculation of molecular energies which then 
parameterized by a wide array of experimentally-
determined structures from crystallographic data of 
receptors and ligands [39]. Therefore, this force field 
provides a more accurate approximation of structural 
conformation, that has a low energy state, in an actual 
wet experimental condition. The compound library then 
prepared for an initial docking validation. 
 
3.3. Docking confirms inhibitory capacity of 
screened ligands 
After the ligand library has been prepared and 
energy minimized, it underwent first validation of 
molecular docking. The library of a total 8166 ligands 
subjected to the active site of EptA soluble domain 
(4KAY). Initially, the protein structure was prepared 
similarly to the ligand preparation. All water and non–
protein molecules, excluding the Zn2+ ion adjacent to 
TPO280 (ZN1), were removed from the structure. 
Missing hydrogens were then added to the structure, 
while partial charges and energy state were corrected 
using AMBER99 force field [47]. AMBER99 is a force 
field built from restrained electrostatic potential (RESP) 
approach [47], which is parameterized for organic and 
large biological molecules [41,42,47]. In the structure 
minimized with a force field, all atoms will find new 
positions that have the lowest energy. However, the 
minimized structure should have no more than 0.1 Å of 
RMS gradient as the higher gradient may possibly 
deviate from the crystallographic structure and no longer 
representative for rational drug discovery. In this 
minimization, the Born approach was used as a 
solvation model, which generates lower energy state 
than other available solvation methods such as 
distance-based and gas-phase.  
After the protein attained its lowest possible energy, 
the docking was then set up. The docking was done in a 
semi-flexible manner, in which the protein structure 
remains rigid whilst the ligands can flexibly find a 
suitable position to obtain the best interaction with target 
receptors. The placement of ligands into the receptors 
used Triangle Matcher algorithm which places ligands 
based on their molecular group charges and spatial 
arrangement. The poses between atoms in the ligand 
and the receptor area of the target protein were 
illustrated as a triangle, where the interaction strength 
and fitness of these triangles are calculated [48]. In this 
first docking validation, 30 best ligand positions were 
retained without duplicates to determine interaction 
score of ligands with the protein. From this result, top 
1000 ligands with lowest Gibbs free binding energy were 
then extracted to a new ligand database file for further 
docking refinement. 
Docking refinement was performed to further assess the 
ligand capability to bind the active site and select the 
ligands with highest inhibitor profile. The refinement was 
done in duplicates with Triangle Matcher and forcefield 
were selected as the methods of placement and 
refinement, respectively. Both refinements used two-
step rescoring, namely London dG and affinity dG to 
calculate the free Gibbs energy of binding (ΔGbinding) 
released from the docking of ligand to the target 
receptor. By contrast with the initial docking validation 
which retained 30 best positions, in these refinements 
100 best ligand positions were retained to gain more 
ligand conformations that create strong interaction with 
the protein which in turn improve the scoring accuracy. 
From two produced docking databases, 20 ligands that 
consensually appeared in the top 100 of both libraries 
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were selected (Table 1) for subsequent molecular 
interaction analyses. 
According to binding energy calculation, all 20 ligands 
significantly have a better binding affinity, ranging from 
one-half to two times more spontaneous than the EptA 
natural substrate PEA. Ligand origins are also equally 
diverse, demonstrating that both pharmacophore and 
ligand-based approaches produce ligands with a good 
inhibition profile. The structures of compounds screened 
from ZincPharmer pharmacophore screening were 
obtained from ZINC database [36], whilst compounds 
selected from PEA similarity search were attained from 
PubChem [37]. 
 
Table (1). Free energy binding score of the best 20 consensus 
ligands obtained from molecular docking refinement protocols 
No ID 
ΔG1 
(kcal/mol) 
ΔG2 
(kcal/mol) 
Average ΔG ± 
std. 
Screening 
1 135135840 -6.935 -6.935 -6.935 Pubchem 
2 7849111 -6.450 -6.238 -6.344 ± 0.150 Pubchem 
3 ZINC35000840 -6.145 -4.585 -5.365 ± 1.103 ZincPharmer 
4 135136215 -6.136 -5.288 -5.712 ± 0.600 Pubchem 
5 26715434 -6.082 -5.839 -5.960 ± 0.172 Pubchem 
6 127259617 -5.873 -4.918 -5.395 ± 0.675 Pubchem 
7 ZINC08101116 -5.796 -5.115 -5.456 ± 0.481 ZincPharmer 
8 ZINC35000842 -5.585 -5.008 -5.296 ± 0.408 ZincPharmer 
9 ZINC08101115 -5.580 -5.520 -5.550 ± 0.042 ZincPharmer 
10 ZINC08101114 -5.563 -4.830 -5.196 ± 0.519 ZincPharmer 
11 49661784 -5.531 -5.001 -5.266 ± 0.375 Pubchem 
12 ZINC13516814 -5.458 -5.317 -5.387 ± 0.099 ZincPharmer 
13 ZINC08101117 -5.357 -4.779 -5.068 ± 0.409 ZincPharmer 
14 ZINC89490588 -5.337 -4.847 -5.092 ± 0.346 ZincPharmer 
15 ZINC08214590 -5.212 -4.902 -5.057 ± 0.219 ZincPharmer 
16 171571760 -5.135 -4.977 -5.056 ± 0.111 ZincPharmer 
17 7848549 -5.021 -4.538 -4.779 ± 0.342 Pubchem 
18 134977160 -5.021 -4.757 -4.889 ± 0.187 Pubchem 
19 ZINC08215878 -5.020 -4.625 -4.823 ± 0.279 ZincPharmer 
20 51091571 -5.000 -5.187 -5.093 ± 0.133 Pubchem 
PEA 
Phosphoethanol
amine 
-3.237 -2.790 -3.013 ± 0.316 N/A 
 
3.4. Interaction analyses and visualization of 
receptor-ligand binding 
Currently, there are no crystallographic EptA 
structures containing in-bound PEA deposited to PDB. 
Therefore, to hypothetically assess the interaction 
between the substrate PEA and EptA, PEA was re-
docked to the whole surface of the EptA soluble domain 
structure (4KAY) using MOE to evaluate its binding 
activities with EptA binding residues. Based on this 
docking, the pose that has the lowest free energy of 
binding was produced when the phosphate group of 
PEA facing inward the known EptA binding pocket. EptA 
PEA binding site is an open and shallow pocket enriched 
in polar residues with the catalytic tetrad Glu240, 
Thr280, Asp452, and His453 as well as coordinately 
linked Zn2+ cofactor positioned at the bottom of the 
pocket. As the most hydrophilic groups in PEA, the 
phosphate group apparently capable to strongly interact 
with the EptA binding pocket and active residues by 
forming electrostatic bridges with polar residues and the 
zinc ion (Figure 2).  
All three negatively-charged oxygens of the 
phosphate form electrostatic contacts with the Zn2+ 
cofactor (ZN2), which is suggested to be essential for 
EptA catalytic activity in transferring PEA to lipid A and 
stabilizing phosphatized Thr280 [5]. Crystallized EptA 
structure used in this study (4KAY) contains three zinc 
ions inside the protein [5]. While one of the zinc ions 
(ZN3) is situated at around 5.5 Å from the catalytic 
tetrad, the other two are located within the catalytic site 
and make contacts with catalytically active residues [5]. 
The first Zn2+ (ZN1) was observed to interact with 
Asp452 and was presumed to be an alternative active 
site of the second zinc ion (ZN2), which is the main 
catalytic site of EptA and located at around 4.4 Å from 
the ZN1 [5].  
 
 
Figure (2). a) two-dimensional and b) three-dimensional 
interaction analyses of PEA (shown in ball and stick 
representation and green carbon) and EptA binding site (grey 
carbon). Salt bridges and other electrostatic interactions are 
represented as blue dashed lines, whereas hydrogen bonds 
are shown in black. 
 
Complementary salt bridges are also formed by the 
phosphate with catalytic residues TPO280 and Glu240. 
The partially positive phosphor electrostatically interacts 
with the carbonyl oxygen of Glu240 side chain, whilst a 
negatively charged oxygen complements the phosphor 
atom of phosphatized Thr280. In addition, hydrogen 
bonds are also formed between the phosphate group 
with two residues of EptA binding surface. The polar 
hydrogen of Ser325 hydroxyl group forms a hydrogen 
bond with the carbon-bound phosphoester oxygen, 
whereas the hydrogen of Gly384 amino backbone forms 
bond with one of the negatively charged oxygens of the 
PEA phosphate group. This complex which contains 
desirable interactions between PEA and EptA active site 
and therefore used as a template for pharmacophore 
screening to search compounds with comparable 
interactions to PEA but a stronger overall binding 
activity. 
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After the best 20 consensus ligands with a better 
docking score than PEA have been determined, their 
molecular interactions with the receptor were identified 
using MOE and Maestro. Overall, most hits share similar 
interaction mode with PEA, in which the polar group(s) 
is situated inside the EptA binding pocket, whereas the 
hydrophobic part of the compound fills the binding 
hallow and make hydrophobic contacts with the pocket 
wall moieties. 
 
3.4.1. Interaction analyses of ligand-based 
compounds 
Ligand 4, 11, 17, and 20 are all obtained from PEA 
similarity search in PubChem [37]. These compounds 
have similarities in structures as well as their interaction 
with the receptor. These ligands have at least four 
carbon rings with polar groups like hydroxyl group that 
are attached to these rings. These properties make 
these compounds capable of binding the enzyme’s polar 
residues and zinc ions as well as making contacts with 
hydrophobic residues surrounding the catalytic cavity 
wall. Further structural search against PubChem 
database revealed that these four compounds are 
approved and registered antibacterials which belong to 
the same family of drugs: tetracyclines, more specifically 
classified as pro-tetracycline drugs [49].  
Tetracycline drugs share molecular features, which 
then determine their minimum pharmacophore [50]. 
Tetracyclines comprise of a fused tetracyclic core [50], 
hence the name, which decorated with various active 
groups serve to enhance their antibacterial activities. 
Tetracyclines act as an antibacterial by disrupting 
protein translation process, specifically in binding 30S 
ribosomes. This prevents aminoacyl transfer RNA to 
bind the messenger RNA and ribosome complex [49]. In 
general, tetracyclines show activity against a broad 
spectrum of bacteria as well as to some fungi and 
protozoan genera [50], even though they are more 
commonly used to combat many Gram-negative 
bacterial infections, including Escherichia coli, 
Enterobacter, Klebsiella, and Neisseria [49]. Although 
tetracyclines activities against bacterial protein 
synthesis process are well established, their actions 
against bacterial antibiotic resistance mechanisms are 
yet to be examined. 
Molecular interaction analyses of these four ligands 
revealed that all ligands interact with at least two 
catalytically important residues of EptA. Ligand4, which 
is better known as meglucycline, interacts with all 
catalytic tetrad as well as two catalytically essential zinc 
ions (Figure 3a). At the bottom of the active site, two 
hydroxyl groups make electrostatic contact, each with 
ZN1 and ZN2. The polar hydrogen atom of one of these 
hydroxyl groups also forms a hydrogen bond with an 
oxygen atom of TPO280 phosphate group. A salt bridge 
is formed between positively-charged nitrogen and the 
carboxylate oxygen of the catalytic Glu240.  
In its best pose, the tail of Ligand4 is bent towards 
the catalytic site which allows this ligand to establish 
additional hydrogen bonds with the catalytic Asp452 and 
His453. A hydrogen of the amine linker creates a 
hydrogen bond with the carbonyl oxygen of Asp452 side 
chain, whilst the hydroxyl group at the end of the 
molecule makes a hydrogen bond with the primary chain 
oxygen of His453. Other hydrogen bonds are also 
formed, mostly with other polar residues, including 
Thr241, Thr242, Ser451, His378, Thr379, and Tyr449. 
As a result, even though Ligand4 forms fewer 
hydrophobic contacts, Ligand4 has the most negative 
binding free energy (-5.712 kcal/mol) compared to other 
tetracycline ligands due to its strong interactions with all 
catalytically important residues and cofactors as well as 
hydrogen bonds with other polar residues of EptA. 
Ligand11 has an average of -5.266 kcal/mol binding free 
energy with EptA and is registered as lymecycline in 
most drug and compound databases. Similar to 
Ligand4, Ligand11 also establishes interactions with 
most of the catalytically pivotal residues and ions, except 
for Glu240 and ZN1 (Figure 3b). Hydroxyl groups in the 
tetracyclic chain still play a key role in binding EptA 
residues where they form a hydrogen bond with TPO280 
and salt bridge with ZN2. Hydrogens of amine groups in 
the tail contribute to establishing hydrogen bonds with 
Asp452 and His453. Other hydrogen bonds are also 
observed between Ligand11 with several EptA residues 
such as Val238, Thr242, Lys328, and Ser451. 
Interestingly, this ligand also forms pi-cation interactions 
between two positively-charged nitrogen atoms of 
different amine groups with the indole ring of Trp320 and 
the phenol ring of Tyr449, respectively.  
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Figure (3). Two-dimensional (left) and three-dimensional 
(right) interaction analyses of: a) Ligand4; b) Ligand11; c) 
Ligand17; and d) Ligand20. Graphical legends are the same 
as in Figure (2). 
 
 Distinct interaction poses are observed in the other 
two ligands, where the tetracycles face outward of 
catalytic cavity rather than inward as in Ligand4 and 
Ligand11. This position causes the last two ligands, 
Ligand17 and Ligand20, unable to bind zinc ions due to 
lack of negatively-charged atoms in their tail to form 
electrostatic interactions with metal ions. The inability to 
form salt bridges with zinc ions significantly reduced 
these two ligands Gibbs free energy of binding.  
 Ligand17 is registered as rolitetracycline and has a 
pyrrolidine ring attached to its main tetracyclic ring. 
Although unable to form an electrostatic contact with 
either zinc ions, the positively-charged pyrrolidine 
nitrogen of the ligand establishes a salt bridge with the 
catalytic Glu240 (Figure 3C). The polar hydrogen in the 
pyrrolidine ring also forms a hydrogen bond with the 
oxygen of TPO280. Ligand17 fails to make interactions 
with other active residues Asp452 and His453. 
Nevertheless, hydroxyl groups in its tetracyclic chain 
maintain hydrogen bonds with several residues such as 
Val238, Lys328, Asp355, and His383. Ligand17 also 
creates another three electrostatic contacts with 
Asp324, His378, and His465. A pi-cation interaction is 
also observed between the positively-charged tertiary 
amine nitrogen with the imidazole ring of His378. 
 Similar to Ligand17, Ligand20 also unable to form an 
interaction with Asp452 and His453 as its tetracyclic 
rings facing outward the catalytic site (Figure 3D). 
Ligand20 is another tetracycline-derived drug commonly 
called pipacycline. The distinct feature of this antibiotic 
is its piperazine ring attached to the main ring of 
tetracycline backbone. The positively-charged nitrogen 
and the polar hydrogens in its piperazine ring provide 
both electrostatic interactions and hydrogen bonds with 
TPO280, respectively. On the one hand, unlike 
Ligand17, Ligand20 maintains an interaction with one of 
zincs, ZN1. This interaction is made by one of the polar 
oxygens of hydroxyl groups and the same oxygen atom 
also creates an electrostatic ring with the partially-
positive phosphor atom of TPO280. Ligand20 also 
successfully manages to make a hydrogen bond with 
Glu240. Other interactions observed in the best pose of 
Ligand20 are hydrogen bonds with Val238, Gly239, 
Lys328, and Thr379. A pi-cation contact is also 
established between the cationic tertiary nitrogen with 
the phenolic ring of Phe288. 
 Overall, ligands derived from similarity search 
performed better in molecular docking assays and 
interaction analyses than the EptA natural substrate 
PEA. These tetracycline derived antibiotics have a lower 
free energy of binding, which represents the high 
spontaneity and stability of the protein-ligand complex 
formation. This result possibly due to a higher number of 
interactions made by the assessed ligands with the 
protein. Although some ligands are incapable to form 
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interactions with several catalytically important residues 
such as Asp452 and His453, other strong interactions 
like hydrogen bonds, electrostatic bridges, and pi-cation 
interactions with the protein residues account for the 
high stability of the formed complex. The ligands also 
have more hydrophobic contacts with the protein than 
PEA. Although this type of interaction has a much lower 
energy than the aforementioned interactions, a higher 
number of hydrophobic contacts could significantly 
contribute to overall ligand binding to the protein 
receptor.  
3.4.2. Interaction analyses of pharmacophore-
based compounds 
 Compounds resulted from ZincPharmer 
pharmacophore screening and validated by molecular 
docking have a various binding mode with the receptor. 
This varied binding mode is influenced by the type of 
molecules, specifically chemical groups attached in their 
structure. Ligand9 and Ligand15 are similar in structure 
in which they consist of three chained sugar or glycoside 
molecules enriched with hydroxyl and amine groups. A 
further search of Ligand9 and Ligand15 in ZINC 
database revealed that these two are well-known 
antibiotics. Ligand9 is gentamicin and Ligand15 is 
kanamycin which both belong to aminoglycoside 
antibacterials. Aminoglycosides are well-known 
antibiotics to treat wide spectrum bacterial infection [51]. 
 The docking with EptA demonstrates that Ligand9 
and Ligand15 have a comparable interaction pose 
(Figure 4B and 4C). They create a number hydrophobic 
contacts as well as strong interactions with catalytically 
active residues such as TPO280 and Glu240. Ligand9 
creates a hydrogen bond between the polar hydrogen of 
a hydroxyl group with the negatively-charged oxygen of 
TPO280 phosphate group. A hydrogen bond is also 
established between the polar hydrogen of an amine 
group with the carbonyl oxygen of Glu240. A similar 
pattern of interaction is also shown by the Ligand15. 
Two of its polar hydrogens makes hydrogen bonds with 
oxygens of TPO280. Whereas Glu240 primary chain of 
EptA serves as both donor and acceptor of hydrogen 
bonds with Ligand15. However, these ligands are 
unable to make interactions with both zinc cofactors and 
the other two catalytic residues Asp452 and His453. 
This may result in an unfavorable inhibition mode 
against EptA which also explain their low binding score. 
 Significantly more extensive interactions with the 
receptor are shown by Ligand3 and Ligand19. Unlike 
previously described pharmacophore-derived 
compounds which are identified as antibiotics, Ligand3  
 
 
 
 
 
 
Figure (4). Two-dimensional (left) and three-dimensional 
(right) interaction analyses of: a) Ligand3; b) Ligand9; c) 
Ligand15; and d) Ligand19. Graphical legends are the same 
as in Figure (2). 
 
and Ligand19 belong to nucleoside compounds: 
guanosine diphosphate (GDP) and deoxyguanosine 
diphosphate (dGDP), respectively. The distinguishing 
factor of these ligands to the other is the presence of 
phosphate groups which mimic the structure of PEA as 
the natural substrate of EptA. Phosphate groups 
possessed by these ligands greatly affect the binding 
with EptA by creating strong interactions with all catalytic 
residues and zinc ions. 
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 In Ligand3 for instance, negatively-charged oxygens 
of the phosphate groups create a salt bridge with both 
Zn2+ ions and the partially positive phosphor atom of 
TPO280. In addition, two positively-charged phosphors 
of both phosphates are able to make electrostatic 
bridges with all catalytic triad residues. The same 
interaction pattern is also apparent in the Ligand19 
where its oxygens and phosphors of phosphate groups 
contribute to the interaction with all catalytic triad and 
zinc cofactors. Both ligands also have bent position 
which allows their hydrophobic moieties to form 
hydrophobic contacts with the protein catalytic cavity 
wall. These interactions create a binding network that 
could possibly increase the binding affinity of ligands, 
decrease their free energy of binding with the protein 
receptor, and increase the overall stability of complex 
formed by the target protein and ligands. 
 
3.5. Combined pharmacophore and ligand-guided 
virtual screening for drug discovery 
 A combination of pharmacophore and substrate 
similarity-based virtual screening was employed in this 
study to search potential EptA inhibitors. 
Pharmacophore screening has been an established 
approach to virtual screening in drug discovery and 
medicinal chemistry in general [52]. This technique 
utilises an algorithmic search of specific spatial and 
chemical arrangement of a compound or 
pharmacophore in the compound database. In the 
present study, pharmacophore screening was 
performed in ZincPharmer [34] platform 
(http://zincpharmer.csb.pitt.edu) which uses the former 
Pharmer [46] algorithm to screen the pharmacophore of 
compounds in ZINC database [36]. ZincPharmer 
screening can be employed to search matched 
compounds using crystal structures of a protein in 
complex with ligands that are available in PDB. 
However, as the crystallographic structure of EptA 
bound with its natural substrate PEA is not available 
anywhere in protein structure databases, the re-docked 
EptA-PEA complex structure was used in the screening. 
In addition to the pharmacophore screening, PEA 
structural ligand-based similarity search was also done 
to enhance breadth and diversity of assessed ligands as 
well as to compare and combine both approaches. The 
search was done in PubChem [37] by using its structure 
search tool (available in 
https://pubchem.ncbi.nlm.nih.gov/). Some antibiotics 
and antibacterials were also included in the library. This 
combined screening produced a library of 8166 hits for 
further molecular docking validation. 
 Molecular docking validation was done in two 
independent step using different scoring and refinement 
parameters. This approach was applied as a duplication 
to refine docking result and to reduce bias. Best 20 
ligands were selected based on their binding energy 
upon docking with the EptA catalytic site, which are 
lower than the EptA natural substrate PEA. Interaction 
analyses of selected ligands demonstrated that most 
ligands maintain essential interactions with EptA. These 
ligands have strong interactions with at least two 
catalytically important residues whilst creating other 
interactions with some EptA residues which contribute 
to their low binding free energy with EptA.  
 A structural search revealed that these ligands are 
well-known antibiotics or active molecules such as 
nucleosides. Four selected ligands from PubChem 
database: Ligand 4, 11, 17, and 20 belong to a group of 
antibiotics called tetracyclines, named meglucycline, 
lymecycline, rolitetracycline, and pipacycline, 
respectively. Tetracyclines have four linearly adjacent 
carbon rings as their backbone structure and are well-
established antimicrobes used to treat a wide range of 
microbial infections and diseases [50]. The antibacterial 
activity of tetracyclines is mainly due to their action in 
preventing the attachment of aminoacyl-tRNA to the 
ribosomal acceptor site during mRNA translation and 
protein synthesis [49,50]. Although the protein synthesis 
inhibition activity of tetracycline is well studied, their 
activity against other potential targets is still 
inadequately studied.  
 The present study demonstrates that tetracyclines 
can potentially be re-purposed to combat antibiotic 
resistance in Gram-negative bacteria by inhibiting one of 
the resistance factors lipid A–PEA transferase (EptA). 
Tetracycline ligands have lower binding free energy and 
overall better binding capacity to the EptA catalytic site 
than PEA. Hydroxyl groups in their tetracyclic ring may 
electrostatically bind zinc ions that are essential for EptA 
catalytic activity. This finding is in accordance with 
earlier experimental studies showing that tetracyclines 
have a strong metal-chelating activity that affects their 
antimicrobial activities [53,54]. 
 ZincPharmer pharmacophore search returned more 
varied hit ligands. Two of selected ligands (Ligand 9 and 
15) are known antibiotics gentamicin and kanamycin, 
respectively. These two compounds belong to the same 
group of antibiotics called aminoglycosides which are 
composed of three sugar molecules or glycosides that 
have amine group modifications. Even though these 
ligands enriched in polar groups such as hydroxyls and 
amines, they failed to make electrostatic contacts with 
zinc cofactors. This is probably due to their orientation 
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during molecular docking where negative charge 
bearing atoms such as oxygen and nitrogen could not 
reach a sufficient distance and a suitable position to 
establish contacts with zinc ions. 
 On the other hand, other selected ligands from 
ZincPharmer screening, Ligand 3 and 19 have notable 
interactions with EptA catalytic site. Ligand 3 and 9, 
known respectively as guanosine diphosphate (GDP) 
and deoxyguanosine diphosphate (dGDP) are examples 
of bioactive molecules belong to nucleosides. These two 
compounds successfully create multiple interactions 
with all EptA catalytically active residues, including the 
catalytic tetrad: Glu240, TPO280, Asp452, and His453 
and two zinc cofactors: ZN1 and ZN2. These binding 
networks are mainly created by the presence of 
phosphate groups in their structure, enabling them to 
mimic the EptA natural substrate PEA and bind all 
pivotal EptA residues. This result demonstrates that 
molecules derived from pharmacophore screening can 
match the spatial and chemical arrangement of the 
template molecule and even enhance their 
pharmacological characteristics such as protein binding 
capacity.  
 These results show that some known antibiotics 
could possibly be re-purposed to combat Gram-negative 
bacteria infection by inhibiting their resistance factor 
EptA. Essential modifications, such as chemical group 
replacement, of these antibiotics might be necessary to 
enhance their susceptibility to bind and inhibit EptA 
catalytic activities. Furthermore, interaction analyses of 
two nucleoside ligands (Ligand 3 and 19) show that 
these compounds create multiple interactions with all 
EptA active residues. These ligands can be further 
tested for their inhibition activity against EptA and be 
developed as new potent inhibitors against the antibiotic 
resistance of Gram-negative bacteria. 
 
CONCLUSION 
 Gram-negative bacteria infection remains a major 
global health concern due to a rapid development of 
multi-drug resistant bacterial strains. The structural 
characterisation of a Gram-negative bacteria resistance 
factor lipid A–PEA transferase (EptA) of Neisseria 
meningitidis has opened a new possibility to combat the 
resistance by developing potent compounds that inhibit 
its activity. In this study, a combined pharmacophore 
and ligand-guided high throughput virtual screening 
were performed to screen potential inhibitors from 
millions of commercially available and registered 
compounds in databases. 
 Initially, more than 8,000 compounds derived from 
both pharmacophore screening in ZincPharmer and 
ligand-based similarity search in Pubmed subjected to 
molecular docking validation and refinement. The 
validation resulted in best 20 consensus ligands that 
have a lower free energy of binding than EptA natural 
substrate PEA. Further interaction analyses suggest 
that eight selected ligands (Ligand 3, 4, 9, 11, 15, 17, 
19, and 20) have overall more interactions with the 
receptor than PEA and maintain essential interactions 
with catalytically active residues and cofactors as well 
as contacts with other residues. Some ligands notably 
have distinct binding mode than others, i.e. Ligand3 and 
Ligand19 that capable of creating a binding network with 
all EptA catalytic tetrad and zinc cofactors. 
Pharmacophore and ligand similarity-based compounds 
from this study can be further studied to evaluate their 
inhibition capability in vitro and in vivo and further 
developed into novel antibacterial agents against multi-
drug resistant Gram-negative bacteria. 
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